November 26, 2025

FDA Grants Accelerated Approval of Voyxact

The subcutaneous injection offers a new option for adults at risk of progression to kidney failure.

Conexiant

November 26, 2025

This Week’s Biopharma News: Texas Takes on BMS and Sanofi

This week’s news roundup reports on Texas’s claim against BMS and Sanofi, AstraZeneca’s Maryland investment, Novo Nordisk’s difficult semaglutide admission, and more.

The Medicine Maker

November 25, 2025

FDA Approves Reformulated Ranitidine

The reformulated heartburn medication comes with strict storage requirements

Conexiant

November 25, 2025

FDA OKs First SMA Gene Replacement Therapy

The FDA approved Itvisma, the first gene replacement therapy for children 2 years and older, teens, and adults with spinal muscular atrophy, a one-time treatment that replaces the SMN1 gene and demonstrated improved motor function in Phase 3 studies.

Conexiant

November 24, 2025

‘It Should Have Never Been Published’ Debate Continues

Experts counter Robert F. Kennedy Jr.’s claims about aluminum adjuvant safety, noting extensive evidence that aluminum-containing vaccines remain effective and well-validated.

KFF Health News

November 21, 2025

‘Gold-Standard Science’ Meets a Rewrite

Revisions to a key CDC webpage have unsettled clinicians, who worry the changes could erode confidence in established vaccine science.

KFF Health News

November 21, 2025

Which Antidepressants Shift Physiology?

Researchers found differences in how antidepressants affect weight, blood pressure, heart rate, and other physiological parameters.

Conexiant

November 18, 2025

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Conexiant

November 17, 2025

‘Patent Dance’ Delays Biosimilars Despite FDA Shift

The FDA moves to speed biosimilar approvals, but rising patent barriers may still delay lower-cost alternatives.

Conexiant